Compare Amgen, Inc. (AMGN) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs iShares Core MSCI Emerging Markets ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while iShares Core MSCI Emerging Markets ETF trades at $79.16. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares Core MSCI Emerging Markets ETF pays none. Which is the better fit depends on your goals.
| AMGN | IEMG | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $388.16 | $86.00 |
52-Week Low | $271.18 | $59.90 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
IEMG trades at $81.33, up 0.38% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF has surged 35% over the past year, driven by strong inflows into emerging markets and a 40% technology weighting, particularly in South Korean and Taiwanese AI-related stocks. Recent news highlights record capital flows and outperformance versus developed markets, though volatility remains elevated.
Outlook is mixed: attractive valuations and AI exposure offer growth potential, but concentration risk and geopolitical tensions pose headwinds. Investors face trade-offs between higher returns and increased volatility, with analyst sentiment cautious due to recent price gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
